Joi + Blokes: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of Joi + Blokes' website, https://joiandblokes.com, FDA Establishment Identifier (FEI) 3044021205, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.

1. 1

   “1. The compounded semaglutide and tirzepatide products displayed on your website identify “Joi + Blokes” on the pictured label, suggesting Joi + Blokes is the compounder of those drugs when in fact it is not.”

2. 2

   ““By utilizing the same bioidentical compound as Ozempic and Wegovy, Blokes can provide a cost-effective alternative.””

3. 3

   ““At Blokes, we offer a cost-effective semaglutide option that is bioidentical with more expensive brands.””

4. 4

   “Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

joiandblokes.com returned a live storefront when we checked in August 2026, trading as a hormone and wellness service with diagnostic lab panels and a running promotional code. The word FDA cited did not appear on the homepage at that check, though we did not review the whole site.

"Bioidentical" is a word to be careful with on a price page, and this is the only letter in the collection that turns on it. It came out of the hormone market, where it distinguishes a molecule that matches what the body makes; it means nothing at all about whether a finished medicine has been reviewed by anyone. Attached to a cost comparison — bioidentical with more expensive brands — it does the same job as "same active ingredient as" while sounding more technical, and FDA read it the same way, saying the claims represent that the products have been evaluated for safety and effectiveness when they have not. If you are choosing between an expensive brand and a cheaper compounded option, the honest version of the sentence is that the molecule is the same and the review is not, and no adjective bridges that gap.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Joi + Blokes failed to respond.